Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts

Anna Falanga, Elliott Shaw, Maria Benedetta Donati, Rossella Consonni, Tiziano Barbui, Stuart Gordon

Research output: Contribution to journalArticle

Abstract

Cancer procoagulant (CP) is a cysteine proteinase from cancer cells that initiates blood coagulation. Members of two classes of unique and highly specific cysteine proteinase inhibitors, peptidyl diazomethyl ketones (PDK) and peptidyl sulfonium salts (PSS), were studied to determine whether or not they inhibited CP. The inhibitors did not impair the activity of the coagulation system. There was a differential inhibitory effect of the 6 PDK and 2 PSS inhibitors, influenced by the amino acid composition or sequence of the peptide moiety, that suggests differences in structural features of the active site of CP and papain. CP was inhibited by both classes of inhibitors.

Original languageEnglish
Pages (from-to)389-398
Number of pages10
JournalThrombosis Research
Volume54
Issue number5
DOIs
Publication statusPublished - Jun 1 1989

Fingerprint

cancer procoagulant
Salts
Cysteine Proteinase Inhibitors
Papain
Cysteine Proteases
Blood Coagulation
Catalytic Domain
Amino Acids
Peptides
peptidyl diazomethyl ketones

Keywords

  • cancer procoagulant
  • coagulation
  • cysteine proteinase
  • cysteine proteinase inhibitor
  • peptidyl diazomethyl ketone
  • peptidyl sulfonium salt

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Hematology

Cite this

Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. / Falanga, Anna; Shaw, Elliott; Donati, Maria Benedetta; Consonni, Rossella; Barbui, Tiziano; Gordon, Stuart.

In: Thrombosis Research, Vol. 54, No. 5, 01.06.1989, p. 389-398.

Research output: Contribution to journalArticle

Falanga, Anna ; Shaw, Elliott ; Donati, Maria Benedetta ; Consonni, Rossella ; Barbui, Tiziano ; Gordon, Stuart. / Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts. In: Thrombosis Research. 1989 ; Vol. 54, No. 5. pp. 389-398.
@article{11c23b797c884bbd880151fc684bb3df,
title = "Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts",
abstract = "Cancer procoagulant (CP) is a cysteine proteinase from cancer cells that initiates blood coagulation. Members of two classes of unique and highly specific cysteine proteinase inhibitors, peptidyl diazomethyl ketones (PDK) and peptidyl sulfonium salts (PSS), were studied to determine whether or not they inhibited CP. The inhibitors did not impair the activity of the coagulation system. There was a differential inhibitory effect of the 6 PDK and 2 PSS inhibitors, influenced by the amino acid composition or sequence of the peptide moiety, that suggests differences in structural features of the active site of CP and papain. CP was inhibited by both classes of inhibitors.",
keywords = "cancer procoagulant, coagulation, cysteine proteinase, cysteine proteinase inhibitor, peptidyl diazomethyl ketone, peptidyl sulfonium salt",
author = "Anna Falanga and Elliott Shaw and Donati, {Maria Benedetta} and Rossella Consonni and Tiziano Barbui and Stuart Gordon",
year = "1989",
month = "6",
day = "1",
doi = "10.1016/0049-3848(89)90209-0",
language = "English",
volume = "54",
pages = "389--398",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Inhibition of cancer procoagulant by peptidyl diazomethyl ketones and peptidyl sulfonium salts

AU - Falanga, Anna

AU - Shaw, Elliott

AU - Donati, Maria Benedetta

AU - Consonni, Rossella

AU - Barbui, Tiziano

AU - Gordon, Stuart

PY - 1989/6/1

Y1 - 1989/6/1

N2 - Cancer procoagulant (CP) is a cysteine proteinase from cancer cells that initiates blood coagulation. Members of two classes of unique and highly specific cysteine proteinase inhibitors, peptidyl diazomethyl ketones (PDK) and peptidyl sulfonium salts (PSS), were studied to determine whether or not they inhibited CP. The inhibitors did not impair the activity of the coagulation system. There was a differential inhibitory effect of the 6 PDK and 2 PSS inhibitors, influenced by the amino acid composition or sequence of the peptide moiety, that suggests differences in structural features of the active site of CP and papain. CP was inhibited by both classes of inhibitors.

AB - Cancer procoagulant (CP) is a cysteine proteinase from cancer cells that initiates blood coagulation. Members of two classes of unique and highly specific cysteine proteinase inhibitors, peptidyl diazomethyl ketones (PDK) and peptidyl sulfonium salts (PSS), were studied to determine whether or not they inhibited CP. The inhibitors did not impair the activity of the coagulation system. There was a differential inhibitory effect of the 6 PDK and 2 PSS inhibitors, influenced by the amino acid composition or sequence of the peptide moiety, that suggests differences in structural features of the active site of CP and papain. CP was inhibited by both classes of inhibitors.

KW - cancer procoagulant

KW - coagulation

KW - cysteine proteinase

KW - cysteine proteinase inhibitor

KW - peptidyl diazomethyl ketone

KW - peptidyl sulfonium salt

UR - http://www.scopus.com/inward/record.url?scp=0024368970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024368970&partnerID=8YFLogxK

U2 - 10.1016/0049-3848(89)90209-0

DO - 10.1016/0049-3848(89)90209-0

M3 - Article

C2 - 2772865

AN - SCOPUS:0024368970

VL - 54

SP - 389

EP - 398

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 5

ER -